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A b s t r a c t
Background: Due to the increasing number of patients placed on waiting lists for orthotopic heart transplantation (OHT), the 
selection of patients with the highest risk of death has become paramount.
Aim: This study aimed to evaluate the predictive value of the Model for End-stage Liver Disease eXcluding INR (MELD-XI) and 
Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) scales in ambulatory patients awaiting OHT and compare 
them to the Heart Failure Survival Score (HFSS).
Methods: The study was a retrospective review of 370 adult ambulatory patients with end-stage heart failure, who were 
added to the OHT waiting list at our institution between 2012 and 2016. 
Results: The median age of the patients was 54.0 (46.0–60.0) years, and 324 (87.6%) of them were male. The overall one-year 
mortality was 27.6%. The areas under the curve (AUCs) for the MAGGIC and HFSS scales were comparable: 0.771 (95% con-
fidence interval [CI] 0.720–0.823); sensitivity 77%, specificity 68% vs. 0.781 (95% CI 0.732–0.829); sensitivity 90%, specificity 
58%, respectively. The AUC for the MELD-XI scale was higher than that for the HFSS scale: 0.812 (95% CI 0.769–0.856); 
sensitivity 91%, specificity 63% vs. 0.781 (95% CI 0.732–0.829) sensitivity 90%, specificity 58%, respectively.
Conclusions: Our study demonstrated that elevated MELD-XI and MAGGIC scores and lowered HFSS scores were associated 
with an increased risk of death during one-year follow-up. The prognostic utility of the MELD-XI scoring system was better 
than that of the HFSS scale, while the MAGGIC scale was comparable to the HFSS.
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INTRODUCTION
Heart failure (HF) is a complex clinical syndrome that repre-
sents a common final pathway of many cardiovascular diseases 
and is associated with high morbidity and mortality [1, 2]. In 
patients with end-stage HF, who remain symptomatic despite 
optimal medical therapy, orthotopic heart transplantation 
(OHT) is the treatment of choice [1–3]. Due to the constantly 
increasing number of patients placed on transplant waiting 
lists and the global shortage of donor hearts, it is of paramount 
importance to perform accurate risk-of-death stratification 
and to allocate organs to those patients who will benefit the 
most from this form of treatment [3, 4]. Over the years, many 
prognostic models have been developed to accurately predict 
the risk of death in patients with end-stage HF, each with their 
own set of advantages and limitations [1, 5]; however, only 
the Heart Failure Survival Score (HFSS) was derived from and 
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validated in a cohort of ambulatory HF patients referred for 
OHT [6]. This model is based on HF aetiology, maximal oxygen 
uptake (VO2max), resting heart rate, mean arterial blood pres-
sure, serum sodium, left ventricular ejection fraction (LVEF), 
and interventricular conduction delay [6]. Despite its proven 
usefulness in the assessment of the risk of death in clinically 
stable patients with end-stage HF [6–8], the HFSS scoring 
system has some limitations. Patients with advanced HF often 
cannot achieve a true peak VO2 due to leg fatigue, general de-
bilitation, or lack of motivation. In addition, VO2max depends 
on many other factors that can significantly influence the test 
results, such as age, sex, body weight, anaemia, lung diseases, 
angina, orthopaedic disorders, skeletal muscle strength, and 
peripheral circulation [9, 10]. It should also be emphasised 
that the HFSS scale has been validated and developed since 
the late 1990s, when only a minimal proportion of patients 
were treated with the use of b-blockers and cardiac resynchro-
nisation therapy or implantable cardioverter-defibrillators [6]. 
Given the substantial survival benefit conferred by b-blockers 
and implantable devices, the clinical usefulness of the HFSS 
scale in the modern HF therapy may be limited. Therefore, 
the prognostic utility of this scoring system should be tested 
in current patient populations. Finally, the HFSS scale does 
not take into consideration the unfavourable prognostic value 
of liver and kidney dysfunctions, pharmacological treatment, 
or the presence of other comorbidities [1, 3, 9, 11, 12]. The 
above parameters constitute the basis of two simple prognostic 
scales: the Model for End-stage Liver Disease eXcluding INR 
(MELD-XI) [5, 13] and the Meta-Analysis Global Group in 
Chronic Heart Failure (MAGGIC) scale, which takes into ac-
count easily available clinical and laboratory data, pharmaco-
logical treatment, and comorbidities [14]. The main advantage 
of these prognostic scales is that they include simple, cheap, 
and routinely assessed laboratory and clinical parameters.
This study aimed to evaluate the predictive value of 
the MELD-XI and MAGGIC scales in ambulatory patients 
awaiting OHT, and to compare their usefulness to that of the 
HFSS scoring system, which is a validated prognostic tool in 
ambulatory patients with end-stage HF.
METHODS
The study was a retrospective review of the clinical records of 
491 ambulatory end-stage HF patients aged 18 years or older, 
who were placed on the OHT waiting list at our institution 
between 2012 and 2016. Patients removed from the waiting 
list because of improvement, deterioration, or withdrawal of 
consent (n = 81) as well as subjects who underwent OHT 
(n = 40) during the follow-up period were excluded from 
the analysis. The resulting study sample comprised 370 par-
ticipants.
All the included patients were on optimal medical 
therapy, resynchronisation therapy, and/or a defibrillator, if ap-
propriate, in accordance with the guidelines of the European 
Society of Cardiology [1].
The basic clinical data and the routinely measured labora-
tory parameters considered by the evaluated prognostic scales 
were collected by reviewing the electronic chart data that 
had been used as the basis for admission to the OHT waiting 
list. The endpoint was defined as all-cause mortality within 
12 months. If a patient failed to attend a scheduled visit, his or 
her survival status was obtained through a telephone interview 
with the patient or a family member.
The HFSS score was calculated based on the following 
equation incorporating seven variables: ([0.0216 × resting 
heart rhythm] + [–0.0255 × mean arterial blood pres-
sure] + [−0.0464 × LVEF] + [–0.0470 × serum sodi-
um] + [–0.0546 × peak VO2] + [0.6083 × presence (1) 
or absence (0) of interventricular conduction defect (QRS 
duration ≥ 0.12 due to any cause)] + [0.6931 × presence (1) 
or absence (0) of ischaemic cardiomyopathy]), as described 
previously [6].
We also calculated the MELD-XI scores using a well-de-
fined formula, where ln –– log normal [13]:
MELD-XI = 5.11 × (ln of total bilirubin in mg/dL) + 
+ 11.76 × (ln of creatinine in mg/dL) + 9.44.
The lower limit of all variables in the MELD-XI scale was 
set at 1.0 mg/dL, and the upper limit for creatinine was set 
at 4.0 mg/dL.
The calculator available at www.heartfailurerisk.org was 
used to determine the score of the MAGGIC scale developed 
by Pocock et al. [14]. The scale includes 13 parameters: 
(1) age, (2) sex, (3) body mass index, (4) systolic blood pressure, 
(5) creatinine concentration, (6) presence or absence of diabetes 
mellitus and (7) chronic obstructive pulmonary disease, (8) HF 
diagnosed within the last 18 months, (9) New York Heart As-
sociation (NYHA) class, (10) LVEF, (11) current smoking status, 
(12) b-blockers, and (13) angiotensin converting enzyme inhibi-
tors (ACEIs) or angiotensin receptor blockers (ARBs).
Statistical analysis
All statistical analyses were carried out using SAS software, 
version 9.4 (SAS Institute Inc., Cary, NC, USA). Data were 
expressed as means and standard deviations or medians and 
interquartile ranges (continuous variables), or as numbers and 
percentages (categorical variables). Intergroup differences 
between continuous variables were tested using Student t test 
or Mann-Whitney U test, while χ2 test was used to analyse 
categorical variables. The receiver operating characteristic 
(ROC) curve was created to determine the utility of the anal-
ysed scales in distinguishing survivors from non-survivors. The 
prognostic strength of the scales was evaluated by calculating 
each area under the curve (AUC) from the ROC analysis for 
one-year motrality. An AUC > 0.7 was considered clinically 
relevant [15]. AUCs from ROC analysis were compared to 
identify the scale that had a stronger association with the 
endpoint. A difference of ≥ 0.025 between the AUCs was con-
sidered clinically relevant [16–18]. The optimal cut-off value 
for the models was determined by using the Youden index. 
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Table 1. Components of the evaluated scales at the time of listing
Variable All patients  
(n = 370)
Survivors  
(n = 268)
Non-survivors 
(n = 102)
p
MAGGIC components:
Age [years] 54 (46–60) 54 (45–59) 54.5 (49–60) 0.64
Male sex 324 (87.6) 234 (87.3) 90 (88.2) 0.81
NYHA class III 263 (71.1) 211 (78.7) 52 (51) < 0.001
NYHA class IV 107 (28.9) 57 (21.3) 50 (49) < 0.001
BMI [kg/m2] 26.0 ± 4.4 25.9 ± 4.4 26.5 ± 4.3 0.17
Resting SBP [mmHg] 110 (90–110) 100 (90–110) 95 (90–101) 0.006
Type 2 diabetes 134 (36.2) 87 (32.5) 47 (46.1) 0.04
COPD 24 (6.5) 15 (5.6) 9 (8.8) 0.40
Current smoker 0 (0) 0 (0) 0 (0)
HF diagnosed within the last 18 months 0 (0) 0 (0) 0 (0)
ACEIs/ARBs 343 (92.7) 252 (94.0) 91 (89.2) 0.11
b-blockers 347 (93.8) 253 (94.4) 94 (92.2) 0.61
HFSS components:
Ischaemic aetiology of HF 164 (44.3) 124 (46.3) 40 (39.3) 0.03
Resting HR [bpm] 77 (69–84) 75 (65–81) 81.5 (74–86) < 0.001
Resting mean BP [mmHg] 76.7 (70.0–83.3) 76.7 (70–83.3) 73.3 (70–80) 0.01
QRS > 0.12 s 150 (40.5) 101 (37.7) 49 (48.0) 0.07
VO2 max [mL/kg/min] 12.3 (10.3–14.1) 13.1 (11.4–14.6) 12.3 (10.0–14.6) 0.12
Sodium [mmol/L] 136.0 (133.0–140.0) 137.5 (134.0–141.0) 132.5 (130.0–136.0) < 0.001
MELD-XI components:
Total bilirubin [µmol/L] 18.4 (12.10–27.4) 15.9 (11.1–23.1) 27.2 (20.1–37.5) < 0.001
Common to MELD-XI and MAGGIC:
Creatinine [µmol/L] 103.0 (85.0–130.0) 94.5 (81.5–118.0) 127.5 (103.0–143.0) < 0.001
Common to HFSS and MAGGIC:
LVEF [%] 18.0 (15.0–20.0) 18.0 (15.0–20.0) 17.5 (15.0–20.0) 0.15
Scores:
HFSS 7.56 (7.04–8.07) 7.82 (7.23–8.25) 7.05 (6.81–7.37) < 0.001
MELD-XI 12.7 (10.0–15.9) 11.3 (9.4–14.3) 16 (13.7–17.9) < 0.001
MAGGIC 26 (24–29) 25 (23–27) 28 (27–30) < 0.001
Data are presented as medians (interquartile range), means (standard deviation) or numbers (percentages) of patients. ACEIs — angiotensin  
converting enzyme inhibitors; ARBs— angiotensin II receptor blockers; BMI — body mass index; BP — blood pressure; COPD — chronic  
obstructive pulmonary disease; HF — heart failure; HFSS— Heart Failure Survival Score; HR — heart rhythm; LVEF — left ventricular ejection  
fraction; MAGGIC — Meta-Analysis Global Group in Chronic Heart Failure; MELD-XI — Model for End-stage Liver Disease eXcluding INR;  
NYHA — New York Heart Association; SBP — systolic blood pressure; VO2max — maximal oxygen uptake
Each result was presented as the AUC with its 95% confidence 
interval (CI), sensitivity, and specificity. A p-value < 0.05 was 
considered statistically significant.
RESULTS
The final study group consisted of 370 ambulatory patients 
with advanced HF in NYHA classes III (71.1%) and IV (28.9%) 
placed on the OHT waiting list. All patients were in profiles 
4 to 7 according to the Interagency Registry for Mechanically 
Assisted Circulatory Support (INTERMACS) classification. In 
the overall population, the median age of the participants 
was 54.0 (46.0–60.0) years; 87.6% of them were male. All 
patients were receiving resynchronisation or defibrillator 
therapy (41.1% and 58.9%, respectively). The devices were 
implanted more often in primary than in secondary preven-
tion of sudden cardiac death (84% vs. 16%, respectively). 
Overall, the patients were on optimal medical therapy, which 
included maximum tolerated doses of b-blockers (93.8% of 
the patients), ACEIs or ARBs (93.2%), aldosterone antagonists 
(96.8%), as well as diuretics (100%). Table 1 summarises the 
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components of the evaluated scales at the time of listing. 
Table 2 includes additional information on comorbidities and 
treatment of the analysed population.
At the end of the follow-up, there were 102 (27.6%) 
non-survivors and 268 (72.4%) survivors.
The ROC curves for the MELD-XI, MAGGIC, and HFSS 
scales for one-year mortality are presented in Figures 1 to 3. All 
analysed scales displayed significant discriminatory power 
(p < 0.001). Table 3 presents results obtained from the ROC 
analysis for all analysed scales.
The prognostic value of the MELD-XI scale was higher 
than that of the HFSS, as indicated by a larger AUC as well 
as a higher sensitivity and specificity (Table 3). The differ-
ence between the calculated AUC for MELD-XI and HFSS 
amounted to 0.0306, which was considered clinically relevant 
(≥ 0.025) [16–18]. The prognostic value of the MAGGIC and 
HFSS scales was comparable: the MAGGIC scale showed 
slightly worse sensitivity and slightly higher specificity than the 
HFSS (Table 3). Furthermore, the difference between 
the calculated AUCs for MAGGIC and HFSS amounted 
to 0.0106, which was considered clinically non-relevant 
(< 0.025) [16–18].
DISCUSSION
Based on a single-centre experience, we demonstrated 
that the HFSS scale continues to provide useful prognostic 
information in patients with end-stage HF receiving optimal 
contemporary therapy. Furthermore, our study showed that 
the MELD-XI and MAGGIC scales are both useful tools for 
predicting OHT waiting list mortality in the population of 
ambulatory patients with end-stage HF. Moreover, it should be 
noted that in terms of prognostic utility the MELD-XI scoring 
system was better than the HFSS scale, while the MAGGIC 
scale was comparable to the HFSS scale in our study group.
Accurate risk stratification is a fundamental component 
of the management strategy for end-stage HF patients await-
ing OHT [19]. A valuable method for outcome prediction is 
constituted by the use of prognostic scales that estimate the 
risk of death holistically, taking into account many significant 
factors and allowing for a better evaluation of the prognosis 
than that enabled by analysing single variables [19, 20]. One 
of the well-established prognostic tools for the discussed 
group of patients is the HFSS scale. Its prognostic strength in 
our analysis was comparable to that reported in the study by 
Aaronson et al. [6]. It should be noted that our study differed 
Table 2. Complementary characteristics of the patients — comorbidities and treatment
Variable All patients 
(n = 370)
Survivors  
(n = 268)
Non-survivors 
(n = 102)
p
Comorbidities:
Arterial hypertension 151 (40.8) 116 (43.3) 35 (34.3) 0.23
Pulmonary hypertension 202 (54.6) 136 (50.7) 68 (66.7) 0.006
Persistent atrial fibrillation 162 (43.8) 117 (43.7) 45 (44.1) 0.94
Hypercholesterolaemia 182 (49.2) 148 (55.2) 34 (33.3) < 0.001
Medications:
Loop diuretics 370 (100) 268 (100) 102 (100)
Thiazide diuretics 120 (32.4) 80 (29.9) 40 (39.2) 0.09
MRA 358 (96.8) 263 (98.1) 95 (93.1) 0.02
Statin 227 (61.4) 177 (66) 50 (49) 0.003
Coumarin derivatives 188 (50.8) 136 (50.7) 52 (51) 0.97
Acetylsalicylic acid 153 (41.1) 113 (42.2) 40 (39.2) 0.61
ICD/CRT-D 370 (100) 268 (100) 102 (100)
Data are presented as numbers (percentages) of patients. CRT-D — cardiac resynchronisation therapy with defibrillator; ICD — implantable 
cardioverter-defibrillator; MRA — mineralocorticoid receptor antagonist 
Table 3. Summary of receiver operating characteristic curve analyses for all scales
AUC 95% CI p Cut-off Sensitivity 95% CI Specificity 95% CI
MELD-IX 0.812 0.769–0.856 < 0.001 > 12.5 0.91 0.84–0.96 0.63 0.57–0.69
HFSS 0.781 0.732–0.829 < 0.001 < 7.67 0.90 0.82–0.94 0.58 0.52–0.64
MAGGIC 0.771 0.720–0.823 < 0.001 > 27 0.77 0.68–0.85 0.68 0.62–0.73
AUC — area under the curve; CI — confidence interval; other abbreviations — see Table 1
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Figure 1. Receiver operating characteristic curve for the Model for 
End-stage Liver Disease eXcluding INR scale
Figure 2. Receiver operating characteristic curve for the Heart 
Failure Survival Score
Figure 3. Receiver operating characteristic curve for the Meta-
-Analysis Global Group in Chronic Heart Failure scale
assist device (LVAD) implantation during one-year follow-up. 
We used one-year mortality as the endpoint for the analysed 
group of patients. Patients dependent on mechanical support 
as well as subjects undergoing OHT during the follow-up were 
excluded from the analysis to increase the homogeneity of the 
population and to reduce bias associated with the different 
weight of factors in a composite endpoint. We considered the 
fact that it is not the clinical status, but the donor-recipient 
matching in terms of size and blood group that is the main 
parameter considered when allocating organs to UNOS 
status 2 heart transplant candidates. Goda et al. [7] assessed 
a population of 354 patients referred for OHT. The research-
ers demonstrated that the HFSS scale (AUC = 0.72) provides 
good risk stratification in HF patients referred for OHT and 
that combining the HFSS with the Seattle Heart Failure Model 
improves discriminatory power (AUC = 0.77). However, 
the above authors also used a composite endpoint defined 
as death, urgent OHT, or LVAD implantation. Furthermore, 
the proportion of patients receiving ACEIs/ARBs, aldosterone 
antagonists, and b-blockers was unsatisfactory [7].
Lund et al. [8] investigated the prognostic value of the 
HFSS scale in ambulatory patients with advanced HF, who 
were referred for OHT evaluation. The authors demonstrated 
that the HFSS can be successfully used for serial assessment 
of the mortality risk in this group of patients [8]. Although 
the HFSS incorporates a multitude of variables and can ef-
fectively identify patients with poor prognosis, it fails to fully 
address the impact of liver and kidney dysfunction, which are 
conditions commonly observed in the advanced stages of HF. 
Their aetiology in HF has been attributed to haemodynamic 
from the latter analysis in some aspects. We analysed patients 
on an OHT waiting list, whereas the population in Aaronson’s 
study included ambulatory patients aged < 70 years with 
LVEF ≤ 40% referred for OHT evaluation. Furthermore, the 
AUC in Aaronson’s study was calculated from a composite 
endpoint consisting of death without transplantation, United 
Network for Organ Sharing (UNOS) status 1, or left ventricular 
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influence: congestion and decreased blood flow resulting 
from diminished cardiac output. Liver and kidney func-
tions can be accurately assessed using the classic Model for 
End-stage Liver Disease (MELD) scale, but this scoring system 
includes international normalised ratio (INR) and, thus, cannot 
be applied in patients receiving vitamin K antagonists [21]. 
Therefore, MELD-XI, a modification of this scale that does 
not consider INR, appears to be an attractive alternative that 
enables the gathering of prognostic information in patients 
with INR elevated due to therapeutic anticoagulation with 
warfarin [11, 13, 22–24].
In our study, we found that the MELD-XI score allows the 
identification of end-stage HF patients at high risk of death, 
with excellent sensitivity and good discriminatory power. In 
the available literature, there are several studies discussing the 
usefulness of the MELD-XI scale in the assessment of prognosis 
in patients with advanced HF. Kim et al. [11] evaluated the 
utility of the MELD-XI scale in a cohort of 260 advanced HF 
patients referred for OHT evaluation. The researchers found 
that, among all the analysed MELD scores, the MELD-XI score 
was the best predictor of one-year endpoints in patients on 
anticoagulation [11]. The study by Kim et al. [11] had some 
limitations that could have affected the predictive value of 
MELD-XI. No echocardiographic or invasive data and no 
information about the degree of HF were provided; there-
fore, we cannot be sure whether all patients were indeed 
in an advanced stage of the disease. The study also used 
a composite endpoint defined as death/OHT/ventricular as-
sist device requirement, which makes it difficult to determine 
the true effect of the MELD-XI score on each of these event 
types. A study by Yang et al. [25] demonstrated that patients 
with a MELD-XI score > 17 prior to LVAD implantation had 
a significantly worse overall survival, while a decrease in this 
score to < 17 during LVAD support improved post-OHT 
survival. Although the population of that study differed from 
ours, because it included patients with LVADs, the results 
corroborate the importance of the MELD-XI score in terms 
of its prognostic value. Our previous study also showed that 
an elevated MELD-XI score directly before OHT is an inde-
pendent risk factor for worse posttransplant prognosis during 
one-year follow-up [26]. Similar conclusions were reached by 
Farr et al. [21], who reported that the MELD-XI score calcu-
lated at the time of OHT evaluation and immediately before 
the operation is an independent predictor of death within 
one year of OHT. Taken together, the above results indicate 
that liver and renal dysfunctions in patients awaiting OHT 
are associated with worse survival both before and after the 
surgery; therefore, these patients should be monitored closely 
and treated aggressively in order to improve their prognosis.
To the best of our knowledge, this is the first study sup-
porting the use of the MAGGIC scale as a prognostic tool in 
a cohort of patients with advanced HF. We found that the 
MAGGIC scale had good discriminatory power in terms of 
predicting one-year mortality in ambulatory patients await-
ing OHT. The MAGGIC scale was originally developed by 
Pocock et al. [14] based on the data of 39,372 patients 
with HF (NYHA classes I–IV), and it can provide useful 
information about the risk of one- and three-year all-cause 
mortality. We identified only one more publication discuss-
ing the use of the MAGGIC scale in patients with HF. Sartipy 
et al. [27] assessed the population of 51,043 patients from 
the national Swedish Heart Failure Registry. The authors of 
this study demonstrated that the MAGGIC scale has good 
discriminatory power in assessing one-year survival in HF 
patients with NYHA classes I–IV [27]. Unfortunately, in the 
above studies [14, 27], the percentage of patients with NYHA 
classes III and IV was low, which makes it difficult to make 
reliable comparisons with our results. Our study is the first 
to demonstrate that the MAGGIC scale can also provide 
accurate risk stratification in advanced HF patients placed 
on transplant waiting lists. The MAGGIC scale can become 
a very attractive prognostic tool in the near future because it 
allows the estimation of mortality risk based on simple and 
routinely gathered clinical data that are generally available 
for all HF patients. 
Several limitations apply to our study. Firstly, it was 
a single-centre, retrospective analysis and the sample size was 
relatively small. Therefore, larger, multicentre, and prospective 
studies are needed to further confirm the reliability and clinical 
utility of the scales discussed above. Secondly, all the scores 
were calculated only at the time of placement on the OHT 
waiting list, so further studies are needed to determine whether 
serial use of these scales can improve their prognostic value in 
terms of one-year risk of death. Furthermore, our study was 
not sufficiently powered to comment on the mode of death, 
and we have limited our analysis to all-cause mortality. 
In conclusion, this single-centre, retrospective study 
analysed the prognostic effectiveness of three scoring systems 
(MELD-XI, MAGGIC, and HFSS) in ambulatory patients with 
end-stage HF awaiting OHT. Elevated MELD-XI and MAGGIC 
scores and lowered HFSS scores were associated with an 
increased risk of death during one-year follow-up. Moreover, 
it should be noted that the prognostic utility of the MELD-XI 
scoring system was better than that of the HFSS, while the 
MAGGIC scale was comparable to the HFSS in this respect. 
The use of these scoring systems might complement and 
enhance the current OHT evaluation models for ambulatory 
patients with end-stage HF.
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WHAT IS NEW?
This single-centre, retrospective study analysed the prognostic effectiveness of three scoring systems: MELD-XI, MAGGIC,  
and HFSS in ambulatory patients with end-stage heart failure (HF) awaiting orthotopic heart transplantation (OHT). We 
demonstrated that the HFSS scale continues to provide useful prognostic information in patients with end-stage HF re-
ceiving optimal contemporary therapy. Furthermore, our study showed that the MELD-XI and MAGGIC scales are both 
useful tools for predicting heart transplant waiting list mortality in the population of ambulatory patients with end-stage 
HF. Moreover, in terms of prognostic utility the MELD-XI scoring system was better than the HFSS, while the MAGGIC 
scale was comparable to the HFSS. The use of these scoring systems might complement and enhance the current OHT 
evaluation models for ambulatory patients with end-stage HF.
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